Filing Details

Accession Number:
0001178913-22-002093
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-19 16:02:33
Reporting Period:
2022-05-18
Accepted Time:
2022-05-19 16:02:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1534248 Chemomab Therapeutics Ltd. CMMB Pharmaceutical Preparations (2834) 813676773
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1840006 Harris Neil Cohen C/O Chemomab Therapeutics Ltd.,
1 Kendall Sq, Bldg 1400E, Ste 14-105
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Acquisiton 2022-05-18 2,000 $3.19 12,409 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
American Depositary Shares Option to Purchase American Depositary Shares Acquisiton 2022-03-07 6,820 $0.00 6,820 $3.53
American Depositary Shares Option to Purchase American Depositary Shares Acquisiton 2021-04-19 11,884 $0.00 11,884 $27.26
American Depositary Shares Option to Purchase American Depositary Shares Acquisiton 2021-03-16 688 $0.00 688 $13.17
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,820 2032-03-07 No 4 A Direct
11,884 2031-04-19 No 4 A Direct
688 2030-07-15 No 4 A Direct
Footnotes
  1. Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
  2. The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
  3. Includes the previously reported 10,409 ADSs of the Company, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 15, 2022.
  4. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
  5. These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
  6. These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
  7. These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.